1. Home
  2. ACAD vs AVNT Comparison

ACAD vs AVNT Comparison

Compare ACAD & AVNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ACADIA Pharmaceuticals Inc.

ACAD

ACADIA Pharmaceuticals Inc.

N/A

Current Price

$17.18

Market Cap

4.4B

Sector

Health Care

ML Signal

N/A

Logo Avient Corporation

AVNT

Avient Corporation

N/A

Current Price

$43.01

Market Cap

4.1B

Sector

Industrials

ML Signal

N/A

Company Overview

Basic Information
Metric
ACAD
AVNT
Founded
1993
1927
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Major Chemicals
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
4.4B
4.1B
IPO Year
2000
2000

Fundamental Metrics

Financial Performance
Metric
ACAD
AVNT
Price
$17.18
$43.01
Analyst Decision
Buy
Buy
Analyst Count
20
8
Target Price
$30.21
★ $53.13
AVG Volume (30 Days)
★ 2.4M
651.6K
Earning Date
11-04-2026
11-04-2026
Dividend Yield
N/A
★ 2.61%
EPS Growth
★ 69.12
N/A
EPS
0.51
★ 1.77
Revenue
$726,437,000.00
★ $3,835,500,000.00
Revenue This Year
$19.55
$6.78
Revenue Next Year
$13.34
$4.02
P/E Ratio
$34.47
★ $24.48
Revenue Growth
★ 40.45
1.71
52 Week Low
$15.86
$28.50
52 Week High
$30.96
$49.08

Technical Indicators

Market Signals
Indicator
ACAD
AVNT
Relative Strength Index (RSI) 34.82 47.34
Support Level $15.86 $35.57
Resistance Level $22.71 $46.11
Average True Range (ATR) 1.20 1.42
MACD -0.11 -0.34
Stochastic Oscillator 18.38 2.67

Price Performance

Historical Comparison
ACAD
AVNT

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.

About AVNT Avient Corporation

Avient Corp manufactures and sells various chemical and plastic-based products to designers and plastic processors. The firm operates in two reportable segments: Color, Additives and Inks, and Specialty Engineered Materials. The company's product portfolio includes concentrated color and ink blends, plastic resins, and various specialized polymer materials used in industries such as food packaging, construction, transportation, cosmetics, and healthcare. The Color, Additives, and Inks segment and the distribution segment generate maximum revenue. Geographically, the company generates maximum revenue from the United States and Canada, followed by EMEA, Asia, and Latin America.

Share on Social Networks: